These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 31387107)

  • 1. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.
    Mori H; Suzuki H; Matsuzaki J; Tsugawa H; Fukuhara S; Miyoshi S; Hirata K; Seino T; Matsushita M; Masaoka T; Kanai T
    Helicobacter; 2016 Aug; 21(4):286-94. PubMed ID: 26612407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Ban H; Otsuka T; Andoh A; Furuta T
    Helicobacter; 2017 Feb; 22(1):. PubMed ID: 27213463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
    J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.
    Hirata Y; Ohmae T; Yanai A; Sakitani K; Hayakawa Y; Yoshida S; Sugimoto T; Mitsuno Y; Akanuma M; Yamaji Y; Ogura K; Maeda S; Koike K
    Int J Antimicrob Agents; 2012 Apr; 39(4):352-5. PubMed ID: 22321702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
    Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
    Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.
    He XJ; Zeng XP; Jiang CS; Liu G; Li DZ; Wang W
    Dig Dis Sci; 2022 Jan; 67(1):208-215. PubMed ID: 33559090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
    Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
    J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
    Matsuzaki J; Suzuki H; Nishizawa T; Hirata K; Tsugawa H; Saito Y; Okada S; Fukuhara S; Hibi T
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1643-5. PubMed ID: 22203601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
    Nishizawa T; Suzuki H; Nakagawa I; Iwasaki E; Masaoka T; Hibi T
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S167-70. PubMed ID: 19120892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquisition of double mutation in
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    United European Gastroenterol J; 2018 Apr; 6(3):391-397. PubMed ID: 29774152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
    Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
    Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
    Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
    Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
    Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
    Chuah SK; Liang CM; Lee CH; Chiou SS; Chiu YC; Hu ML; Wu KL; Lu LS; Chou YP; Chang KC; Kuo CH; Kuo CM; Hu TH; Tai WC
    Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea.
    Lee JW; Kim N; Nam RH; Park JH; Kim JM; Jung HC; Song IS
    Helicobacter; 2011 Aug; 16(4):301-10. PubMed ID: 21762270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
    Liou JM; Chen CC; Chen MJ; Chang CY; Fang YJ; Lee JY; Sheng WH; Wang HP; Wu MS; Lin JT
    J Antimicrob Chemother; 2011 Aug; 66(8):1847-52. PubMed ID: 21632579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.